Intercept Liver Disease Strategy Bets Heavily On New Surrogate Endpoints

24 Mar 2014
News

Bridget Silverman bridget.silverman@informa.com

Executive Summary

Intercept is aiming to file obeticholic acid for accelerated approval in two liver disease indications and is mining clinical outcomes data to support new surrogate endpoints with the help of a clinical network dubbed the “Supergroup.”

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Clinical Trials Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS056012

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS056012

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Intercept Liver Disease Strategy Bets Heavily On New Surrogate Endpoints

News

Executive Summary

Related Content

Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint

Searching For Surrogate Endpoints Requires Teamwork

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert